{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:21:49Z","timestamp":1787851309214,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108318","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:56:24Z","timestamp":1784926584000},"page":"108318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma: a real-world study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-4483","authenticated-orcid":false,"given":"M.","family":"Sternschuss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-1435","authenticated-orcid":false,"given":"A.","family":"Arbuiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2478-2261","authenticated-orcid":false,"given":"E.","family":"Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6812-8591","authenticated-orcid":false,"given":"N.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Regazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-9297","authenticated-orcid":false,"given":"F.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2041-6199","authenticated-orcid":false,"given":"O.","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Beylergil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Niglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7235-6319","authenticated-orcid":false,"given":"S.A.","family":"Funt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-6099","authenticated-orcid":false,"given":"G.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-5751","authenticated-orcid":false,"given":"D.","family":"Aggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-0070","authenticated-orcid":false,"given":"I.","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2637-4249","authenticated-orcid":false,"given":"J.E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2026.108318_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108318_bib2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108318_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"5 suppl","key":"10.1016\/j.esmoop.2026.108318_bib5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2025.43.5_suppl.770","article-title":"Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin\/pembrolizumab (EVP) in the evolving landscape of locally advanced\/metastatic (la\/m) urothelial cancer (UC)","volume":"43","author":"Chablani","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108318_bib6","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5 suppl","key":"10.1016\/j.esmoop.2026.108318_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.2025.43.5_suppl.664","article-title":"EV-302: updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"43","author":"Powles","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10236","key":"10.1016\/j.esmoop.2026.108318_bib8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108318_bib9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2026.108318_bib10","article-title":"1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)","volume":"33","author":"Szabados","year":"2022","journal-title":"Ann Oncol"},{"issue":"7 suppl","key":"10.1016\/j.esmoop.2026.108318_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2026.44.7_suppl.705","article-title":"Outcomes with subsequent therapies post-enfortumab vedotin\/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): analysis of the UNITE study","volume":"44","author":"Jiang","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108318_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108318_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108318_bib14","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108318_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105862","article-title":"Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study","volume":"10","author":"Maiorano","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108318_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clgc.2022.11.003","article-title":"Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma","volume":"21","author":"Makrakis","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"7 suppl","key":"10.1016\/j.esmoop.2026.108318_bib17","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108318_bib18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602260X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602260X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:34:23Z","timestamp":1787848463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292602260X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S205970292602260X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108318","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma: a real-world study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108318"}}